CompletedPhase 2NCT02230176

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Studying Neuroendocrine carcinoma of pancreas

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Principal Investigator
Eric BAUDIN, MD
Gustave Roussy, Cancer Campus, Grand Paris
Intervention
Sunitinib(drug)
Enrollment
84 enrolled
Eligibility
18 years · All sexes
Timeline
2015 – 2024

Study locations (1)

Collaborators

National Cancer Institute, France · Advanced Accelerator Applications

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02230176 on ClinicalTrials.gov

Other trials for Neuroendocrine carcinoma of pancreas

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine carcinoma of pancreas →

← Back to all trials